Development, Drug Delivery, In-Vivo and Reagent

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Development

Drug Delivery

In-Vivo

Reagent

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

Antibody

Antibody Gene Therapy Gene In-Vitro

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

OCTOBER 1, 2020

And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist

Scientist In-Vitro Research Life Science

Clinical Research Informer

Turning science into business: An optimised alternative to antibodies

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

Stay Connected